IL289784A - isoqc and/or qc enzyme inhibitors - Google Patents

isoqc and/or qc enzyme inhibitors

Info

Publication number
IL289784A
IL289784A IL289784A IL28978422A IL289784A IL 289784 A IL289784 A IL 289784A IL 289784 A IL289784 A IL 289784A IL 28978422 A IL28978422 A IL 28978422A IL 289784 A IL289784 A IL 289784A
Authority
IL
Israel
Prior art keywords
isoqc
pyrrolidine
inhibitors
fused
enzyme
Prior art date
Application number
IL289784A
Other languages
English (en)
Hebrew (he)
Inventor
Evers Bastiaan
E Brennan Paul
Original Assignee
Scenic Immunology B V
Evers Bastiaan
E Brennan Paul
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scenic Immunology B V, Evers Bastiaan, E Brennan Paul filed Critical Scenic Immunology B V
Publication of IL289784A publication Critical patent/IL289784A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
IL289784A 2019-07-12 2022-01-12 isoqc and/or qc enzyme inhibitors IL289784A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19185997 2019-07-12
PCT/EP2020/069630 WO2021009068A1 (en) 2019-07-12 2020-07-10 N-substituted-3,4-(fused 5-ring)-5-phenyl-pyrrolidine-2-one compounds as inhibitors of isoqc and/or qc enzyme

Publications (1)

Publication Number Publication Date
IL289784A true IL289784A (en) 2022-03-01

Family

ID=67262155

Family Applications (1)

Application Number Title Priority Date Filing Date
IL289784A IL289784A (en) 2019-07-12 2022-01-12 isoqc and/or qc enzyme inhibitors

Country Status (12)

Country Link
US (1) US20230077723A1 (cg-RX-API-DMAC7.html)
EP (1) EP3997091A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022542540A (cg-RX-API-DMAC7.html)
KR (1) KR20220054293A (cg-RX-API-DMAC7.html)
CN (1) CN114466849B (cg-RX-API-DMAC7.html)
AU (1) AU2020312647A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022000505A8 (cg-RX-API-DMAC7.html)
CA (1) CA3147154A1 (cg-RX-API-DMAC7.html)
IL (1) IL289784A (cg-RX-API-DMAC7.html)
MX (1) MX2022000521A (cg-RX-API-DMAC7.html)
PH (1) PH12022550079A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021009068A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4717089A3 (en) 2021-08-02 2026-06-24 Syngenta Crop Protection AG Microbiocidal pyrazole derivatives
AU2022203580A1 (en) * 2021-09-17 2023-04-06 Academia Sinica Methods of Increasing Cell Phagocytosis
EP4447682A1 (en) 2021-12-17 2024-10-23 Syngenta Crop Protection AG Microbiocidal pyrazole derivatives
TW202430514A (zh) 2022-09-30 2024-08-01 瑞士商先正達農作物保護股份公司 殺微生物之吡唑衍生物
PY2403614A (es) 2023-01-27 2025-09-11 Syngenta Crop Protection Ag Derivados de pirazol microbiocidas
PY2404467A (es) 2023-02-01 2025-03-31 Syngenta Crop Protection Ag Composiciones fungicidas
EP4455142A1 (en) 2023-04-26 2024-10-30 Scenic Immunology B.V. Novel inhibitor of qpctl and/or qc
PY2447478A (es) 2023-06-14 2025-03-18 Syngenta Crop Protection Ag Composiciones fungicidas
WO2025114167A1 (en) 2023-11-28 2025-06-05 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
AR134999A1 (es) 2024-02-02 2026-05-20 Syngenta Crop Protection Ag Derivados de pirazol microbiocidas
WO2025191053A1 (en) 2024-03-14 2025-09-18 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2025224308A1 (en) * 2024-04-25 2025-10-30 Scenic Immunology B.V. Qpctl inhibitors
WO2026022173A1 (en) 2024-07-26 2026-01-29 Syngenta Crop Protection Ag Microbiocidal pyrazole compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011002106A (es) * 2008-09-04 2011-04-07 Probiodrug Ag Inhibidores novedosos.
US8975417B2 (en) * 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
AU2014272695B2 (en) * 2013-05-28 2016-10-20 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as BET inhibitors and their use in the treatment of disease
KR102084185B1 (ko) * 2013-08-29 2020-03-04 주식회사 대웅제약 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법
WO2019022600A1 (en) * 2017-07-24 2019-01-31 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis TREATMENT OF PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA INTERACTION - CD47

Also Published As

Publication number Publication date
EP3997091A1 (en) 2022-05-18
MX2022000521A (es) 2022-06-14
PH12022550079A1 (en) 2023-04-12
BR112022000505A2 (pt) 2022-03-22
BR112022000505A8 (pt) 2022-04-12
CN114466849A (zh) 2022-05-10
CN114466849B (zh) 2024-07-12
AU2020312647A1 (en) 2022-02-24
KR20220054293A (ko) 2022-05-02
WO2021009068A1 (en) 2021-01-21
US20230077723A1 (en) 2023-03-16
JP2022542540A (ja) 2022-10-05
CA3147154A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
IL279173A (en) Heterocyclic compounds as monoacylglycerol lipase inhibitors
IL280762A (en) Heterocyclic compounds as monoacylglycerol lipase inhibitors
EP3990448A4 (en) HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12C
EP3672973A4 (en) HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USING THEREOF
EP3797109A4 (en) HETEROCYCLIC COMPOUNDS AS KINAS INHIBITORS, COMPOSITIONS CONTAINING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
PH12017502090A1 (en) Heterocyclic amides as kinase inhibitors
EP3962484A4 (en) RAF KINASE INHIBITORS
EP3697791A4 (en) HETEROCYCLIC COMPOUNDS, COMPOSITIONS INCLUDING A HETEROCYCLIC COMPOUND, AND METHODS OF USING THEREOF
IL287026A (en) Heterocyclic compounds and their uses
EP4041198A4 (en) SOLID FORMS OF OMECAMTIV MECARBIL DIHYDROCHLORIDE AND PROCESS THEREOF
EP3448852A4 (en) NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF TYROSINE KINASE BCR-ABL
EP3882247A4 (en) SIX-MEMBERED, SIX-MEMBERED, HETEROCYCLIC COMPOUND AND USES OF THEREOF AS A PROTEIN KINASE RECEPTOR INHIBITOR
IL289783A (en) enzyme inhibitors
TW201613934A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
IL281742A (en) Novel compounds as nadph oxidase inhibitors
EP3744722A4 (en) Ss-LACTAMASE INHIBITOR AND ITS USE
MX2023001805A (es) Formas solidas de 2-(5-(4-(2-morfolinoetoxi)fenil)piridin-2-il)-n- bencilacetamida.
EP3999064A4 (en) Inhibitors of tyrosine kinase
EP3266265A4 (en) Offloading of controlling across access nodes
EA202091691A1 (ru) ТВЕРДЫЕ ФОРМЫ ЗАМЕЩЕННЫХ 5,6-ДИГИДРО-6-ФЕНИЛБЕНЗО[f]ИЗОХИНОЛИН-2-АМИНОВЫХ СОЕДИНЕНИЙ
EP3697416A4 (en) INHIBITORS OF THE MUTED TYROSINE KINASES OF THE EGFR FAMILY
EP3909952A4 (en) SALTS OF HETEROCYCLIC COMPOUND AND USE THEREOF
HK40071644A (en) Heterocyclic inhibitors of tyrosine kinase
AU2017900935A0 (en) Heterocyclic inhibitors of PCSK9
HK40061556A (en) Heterocyclic kinase inhibitors and uses thereof